The ABPI welcomes the Government’s decision to boost the Cancer Drugs Fund (CDF) by £160 million until the fund ends in March 2016 as a positive development towards further improving cancer outcomes for NHS patients in England.Read more
Dr Louise Leong, ABPI Director of R&D Policy, comments on the Medical Research Council’s (MRC) review of the UK molecular pathology landscape.Read more
Pharmaceutical companies invest huge amounts of money and time into the development of new medicines, yet it is the nature of the very difficult research and development (R&D) process that few candidate medicines that enter clinical studies are ultimately approved.Read more
Stephen Whitehead, ABPI Chief Executive, comments on the value assessment of cancer medicines.Read more
Our website is currently experiencing scrolling issues when viewed using Internet Explorer 8. If you are experiencing problems with scrolling please upgrade to a later version of Internet Explorer or use Chrome or Firefox.
Board of Management